Back to Search Start Over

Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation

Authors :
Guan-Nan Li
Xue-Jiao Zhao
Zhen Wang
Meng-Shi Luo
Shen-Nan Shi
Dan-Mei Yan
Hua-Yi Li
Jia-Hao Liu
Yang Yang
Jia-Hong Tan
Ze-Yu Zhang
Ru-Qi Chen
Hui-Ling Lai
Xiao-Yuan Huang
Jian-Feng Zhou
Ding Ma
Yong Fang
Qing-Lei Gao
Source :
Signal transduction and targeted therapy. 7(1)
Publication Year :
2022

Abstract

Finely tuned mitogen-activated protein kinase (MAPK) signaling is important for cancer cell survival. Perturbations that push cells out of the MAPK fitness zone result in cell death. Previously, in a screen of the North China Pharmaceutical Group Corporation’s pure compound library of microbial origin, we identified elaiophylin as an autophagy inhibitor. Here, we demonstrated a new role for elaiophylin in inducing excessive endoplasmic reticulum (ER) stress, ER-derived cytoplasmic vacuolization, and consequent paraptosis by hyperactivating the MAPK pathway in multiple cancer cells. Genome-wide CRISPR/Cas9 knockout library screening identified SHP2, an upstream intermediary of the MAPK pathway, as a critical target in elaiophylin-induced paraptosis. The cellular thermal shift assay (CETSA) and surface plasmon resonance (SPR) assay further confirmed the direct binding between the SHP2 and elaiophylin. Inhibition of the SHP2/SOS1/MAPK pathway through SHP2 knockdown or pharmacological inhibitors distinctly attenuated elaiophylin-induced paraptosis and autophagy inhibition. Interestingly, elaiophylin markedly increased the already-elevated MAPK levels and preferentially killed drug-resistant cells with enhanced basal MAPK levels. Elaiophylin overcame drug resistance by triggering paraptosis in multiple tumor-bearing mouse models resistant to platinum, taxane, or PARPi, suggesting that elaiophylin might offer a reasonable therapeutic strategy for refractory ovarian cancer.

Details

ISSN :
20593635
Volume :
7
Issue :
1
Database :
OpenAIRE
Journal :
Signal transduction and targeted therapy
Accession number :
edsair.doi.dedup.....51520636774d73a4a0db82a0f43b487b